NCT04376840

Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19

Completed NA Last updated 21 January 2026

What this trial tests

NA trial testing Blood sample and data record in Severe SARS-CoV2 Pneumonia in 150 participants. Completed in 29 July 2022.

Timeline

28 May 2020

Primary endpoint
29 July 2022

29 July 2022

Quick facts

Lead sponsor	CHU de Reims
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	150
Start date	28 May 2020
Primary completion	29 July 2022
Estimated completion	29 July 2022
Sites	1 location across France

Drugs / interventions tested

• Blood sample and data record

Conditions studied

• Severe SARS-CoV2 Pneumonia — all drugs for Severe SARS-CoV2 Pneumonia →

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Severe SARS-CoV2 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Studies performed after coronavirus epidemics (severe acute respiratory syndrome coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus, MERS-CoV) have shown a long-term impact on respiratory morbidity, musculoskeletal and psycho-social repercussions.

Patients with SARS-CoV pneumonia had fibrotic pulmonary sequelae at 45 days (lower DLCO in 27.3% of cases and radiological lesions in 21.5% of cases). In the MERS-CoV pneumonia study, patients had radiological sequelae in 33% of cases and the 12-month evaluation showed persistence of radiological abnormalities in 23.7% of the cases despite an improvement in respiratory function.

Clinical presentation and therapeutic management of severe SARS-CoV-2 infection are in part similar to those induced by SARS-CoV and MERS-CoV. Long-term respiratory complications are therefore expected.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Imaging in the COVID-19 era: Lessons learned during a pandemic.
   Sideris GA, Nikolakea M, Karanikola AE, Konstantinopoulou S, et al · · 2021 · cited 7× · PMID 34249239 · DOI 10.4329/wjr.v13.i6.192
2. Cluster analysis unveils a severe persistent respiratory impairment phenotype 3-months after severe COVID-19.
   Perotin JM, Gierski F, Bolko L, Dury S, et al · · 2022 · cited 3× · PMID 35918719 · DOI 10.1186/s12931-022-02111-9